All News

2061 articles, sorted by publication time.

Gene Therapy · global

Pivotal Trial Results Announced for X-Linked Retinitis Pigmentosa Gene Therapy: Low-Light Vision Improves in Some Patients

The pivotal trial of laru-zova showed that about one-quarter to one-third of treated participants met the prespecified threshold for improvement in low-light vision after one year. This progress brings the therapy closer to a marketing application while highlighting the importance of patient selection, surgical risks, and long-term follow-up.

Drug Development · global

Alpha-emitting radiopharmaceutical RYZ101 meets Phase 3 endpoint, offering new insights for neuroendocrine tumors progressing after lutetium-177 treatment

Patients whose disease continues to progress after prior radionuclide therapy may gain another treatment option. RYZ101 has met its primary progression-free survival endpoint, but the magnitude of benefit and detailed safety data have not yet been released, leaving key information needed to establish its clinical value.

Cancer and Immunotherapy · global

Personalized mRNA Cancer Vaccine Reports Phase 3 Success, Reducing the Risk of Melanoma Recurrence After Surgery

A vaccine tailored to each patient’s tumor mutations, combined with immunotherapy, improved recurrence-free and distant metastasis-free survival in a trial involving more than 1,000 participants. However, the announcement summarizes an interim analysis; the magnitude of the benefit and long-term survival results remain to be disclosed.

Biotechnology Industry · global

Competition in AI Drug Discovery Extends to Partnership Networks: Strategy Survey of 25 Companies Maps Industry Roles

Pharmaceutical companies integrate AI into R&D workflows, AI startups build platforms and drug candidates, and technology giants supply models and computing power. A Japanese strategy survey describes how these three groups connect their resources, while leaving a key question: can these partnerships translate into verifiable drug development outcomes?

Clinical Trials · global

Vision improvement meets target, but safety gap emerges: remigromig reports diabetic eye disease trial results

A novel antibody that activates Wnt signaling met the noninferiority criterion against the comparator drug for one-year vision outcomes but did not demonstrate superior efficacy. A higher rate of adverse events related to proliferative retinopathy calls for a more detailed assessment of the benefits and risks of this new treatment approach.